First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of anti Siglec-15 PYX-106 in Subjects with Advanced Solid Tumors Poster Number: 756 By Jonathan First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of anti Siglec-15 PYX-106 in Subjects with Advanced Solid Tumors Poster Number: 756 Read More »
A First-in-Human Phase 1 Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of the EDB+FN targeting ADC PYX-201 in Participants with Advanced Solid Tumors Poster Number: 762 By Jonathan A First-in-Human Phase 1 Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of the EDB+FN targeting ADC PYX-201 in Participants with Advanced Solid Tumors Poster Number: 762 Read More »
A Phase 2 Trial with a Safety Lead-in to Evaluate the Addition of Sotigalimab, a CD40 Agonistic Monoclonal Antibody, to Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcoma By lsc-webmaster A Phase 2 Trial with a Safety Lead-in to Evaluate the Addition of Sotigalimab, a CD40 Agonistic Monoclonal Antibody, to Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcoma Read More »
Tissue Assessment of Therapeutic Responses to Neoadjuvant SCRT with and without Anit-CD40 Immunotherapy Sotigalimab (Sotiga) in Rectal Cancer By lsc-webmaster Tissue Assessment of Therapeutic Responses to Neoadjuvant SCRT with and without Anit-CD40 Immunotherapy Sotigalimab (Sotiga) in Rectal Cancer Read More »
Use of High-dimensional and Spatial Immune Profiling to Explore Sotigalimab (CD40 Agonist) Activation of Antigen Presenting Cells and T Cells in the Tumor Microenvironment in Patients with Esophageal/Gastroesophageal Junction Cancer By lsc-webmaster Use of High-dimensional and Spatial Immune Profiling to Explore Sotigalimab (CD40 Agonist) Activation of Antigen Presenting Cells and T Cells in the Tumor Microenvironment in Patients with Esophageal/Gastroesophageal Junction Cancer Read More »
A Multicenter Phase 2 Study of Sotigalimab (CD40 Agonist) in Combination with Neoadjuvant Chemoradiation for Resectable Esophageal and Gastroesophageal Junction (GEJ) Cancers By lsc-webmaster A Multicenter Phase 2 Study of Sotigalimab (CD40 Agonist) in Combination with Neoadjuvant Chemoradiation for Resectable Esophageal and Gastroesophageal Junction (GEJ) Cancers Read More »
Elucidating Factors of Therapeutic Response to Immunotherapy Combined with Neoadjuvant Radiation Therapy for Rectal Cancer By lsc-webmaster Elucidating Factors of Therapeutic Response to Immunotherapy Combined with Neoadjuvant Radiation Therapy for Rectal Cancer Read More »
Multi-Omic Multi-Parameter Circulating Biomarker Analysis in Chemoimmunotherapy Combinations Identifies Unique Immune Activation Signatures in the Pancreatic Cancer Setting By lsc-webmaster Multi-Omic Multi-Parameter Circulating Biomarker Analysis in Chemoimmunotherapy Combinations Identifies Unique Immune Activation Signatures in the Pancreatic Cancer Setting Read More »
Phase II of CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy By lsc-webmaster Phase II of CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy Read More »
Innate: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer to Elucidate Local and Systemic Therapeutic Response By lsc-webmaster Innate: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer to Elucidate Local and Systemic Therapeutic Response Read More »
